What are your considerations for choice of immunotherapy agent with patients with metastatic pMMR HER2- esophageal/GEJ/gastric adenocarcinoma with CPS >=10?
Are there meaningful differences in the CHECKMATE 649 and KEYNOTE 590 studies to guide this decision?